Affordable Access

Access to the full text

Long-Term Molecular Remission Achieved by Antibody Anti-CD22 and Ponatinib in a Patient Affected by Ph’+ Acute Lymphoblastic Leukemia Relapsed after Second Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report

Authors
  • Pirosa, Maria Cristina
  • Leotta, Salvatore
  • Cupri, Alessandra
  • Stella, Stefania
  • Martino, Enrica Antonia
  • Scalise, Luca
  • Sapienza, Giuseppe
  • Calafiore, Valeria
  • Mauro, Elisa
  • Spadaro, Andrea
  • Vigneri, Paolo
  • Di Raimondo, Francesco
  • Milone, Giuseppe
Type
Published Article
Journal
Chemotherapy
Publisher
S. Karger AG
Publication Date
Oct 29, 2018
Volume
63
Issue
4
Pages
220–224
Identifiers
DOI: 10.1159/000492941
PMID: 30372691
Source
Karger
Keywords
License
Green
External links

Abstract

Ph’+ acute lymphoblastic leukemia (Ph’+-ALL) is an oncohematologic disorder for which allogeneic bone marrow transplantation still offers the only chance of cure. However, relapse is the main reason for treatment failure, also after hematopoietic stem cell transplantation (HSCT). New drugs, such as third generation tyrosine kinase inhibitors (TKIs) and monoclonal antibodies, have expanded the therapeutic landscape, especially in patients who relapsed before HSCT. Very few reports, up to now, have described the use of both classes of these new agents in combination with donor lymphocyte infusions (DLI) in the setting of patients who relapsed after HSCT. We report on a young patient affected by Ph’+-ALL, who relapsed after the second HSCT and who reached molecular remission and long-term disease control by treatment with the anti-CD22 monoclonal antibody inotuzumab ozogamicin, DLI, and the 3rd generation TKI ponatinib.

Report this publication

Statistics

Seen <100 times